Neurologix, Inc. (NRGX.OB)


Neurologix, Inc. is a development-stage company engaged in the research and development of proprietary treatments for disorders of the brain and central nervous system utilizing gene therapies. The Company's initial development efforts are focused on gene therapy for treating Parkinson's disease, epilepsy and other neurodegenerative and metabolic disorders. Neurologix's core technology, "NLX," is currently in clinical stages of development, having recently completed a Phase I human clinical trial to treat Parkinson's disease and with additional trials in that indication and in epilepsy planned.

Contact Information

One Bridge Plaza
Fort Lee, NJ 07024

tel: 201-592-6451
fax: 203-661-1331


Investor Relations



Exchange: OTCBB
Industry: Drug Manufacturers - Major
Market Cap: $20.1M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.